Laurence Zitvogel
Laurence Zitvogel
Institut Gustave Roussy, Université de Paris Saclay, INSERM
Verified email at
Cited by
Cited by
Exosomes: composition, biogenesis and function
C Théry, L Zitvogel, S Amigorena
Nature reviews immunology 2 (8), 569-579, 2002
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
L Galluzzi, I Vitale, SA Aaronson, JM Abrams, D Adam, P Agostinis, ...
Cell Death & Differentiation 25 (3), 486-541, 2018
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ...
Science 359 (6371), 91-97, 2018
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V Gopalakrishnan, CN Spencer, L Nezi, A Reuben, MC Andrews, ...
Science 359 (6371), 97-103, 2018
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ...
Nature medicine 13 (9), 1050-1059, 2007
Calreticulin exposure dictates the immunogenicity of cancer cell death
M Obeid, A Tesniere, F Ghiringhelli, GM Fimia, L Apetoh, JL Perfettini, ...
Nature medicine 13 (1), 54-61, 2007
Innate or adaptive immunity? The example of natural killer cells
E Vivier, DH Raulet, A Moretta, MA Caligiuri, L Zitvogel, LL Lanier, ...
science 331 (6013), 44-49, 2011
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ...
Science 350 (6264), 1079-1084, 2015
Immunogenic cell death in cancer therapy
G Kroemer, L Galluzzi, O Kepp, L Zitvogel
Annual review of immunology 31, 51-72, 2013
Antigen presentation and T cell stimulation by dendritic cells
P Guermonprez, J Valladeau, L Zitvogel, C Théry, S Amigorena
Annual review of immunology 20 (1), 621-667, 2002
Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes
L Zitvogel, A Regnault, A Lozier, J Wolfers, C Flament, D Tenza, ...
Nature medicine 4 (5), 594-600, 1998
Immunogenic cell death in cancer and infectious disease
L Galluzzi, A Buqué, O Kepp, L Zitvogel, G Kroemer
Nature Reviews Immunology 17 (2), 97-111, 2017
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
F Ghiringhelli, L Apetoh, A Tesniere, L Aymeric, Y Ma, C Ortiz, ...
Nature medicine 15 (10), 1170-1178, 2009
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide
S Viaud, F Saccheri, G Mignot, T Yamazaki, R Daillère, D Hannani, ...
science 342 (6161), 971-976, 2013
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
J Wolfers, A Lozier, G Raposo, A Regnault, C Théry, C Masurier, ...
Nature medicine 7 (3), 297-303, 2001
Immunological aspects of cancer chemotherapy
L Zitvogel, L Apetoh, F Ghiringhelli, G Kroemer
Nature reviews immunology 8 (1), 59-73, 2008
The immune contexture in cancer prognosis and treatment
WH Fridman, L Zitvogel, C Sautès–Fridman, G Kroemer
Nature reviews Clinical oncology 14 (12), 717-734, 2017
Cancer despite immunosurveillance: immunoselection and immunosubversion
L Zitvogel, A Tesniere, G Kroemer
Nature reviews immunology 6 (10), 715-727, 2006
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
N Casares, MO Pequignot, A Tesniere, F Ghiringhelli, S Roux, N Chaput, ...
The Journal of experimental medicine 202 (12), 1691-1701, 2005
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F Ghiringhelli, C Menard, PE Puig, S Ladoire, S Roux, F Martin, E Solary, ...
Cancer immunology, immunotherapy 56, 641-648, 2007
The system can't perform the operation now. Try again later.
Articles 1–20